NCT00303459View on ClinicalTrials.gov

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

PHASE4CompletedINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

bosentan

bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.

DRUG

placebo

Matching bosentan placebo/b.i.d.

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY

NCT00303459 - Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) | Biotech Hunter | Biotech Hunter